Dibenzylfluorescein (DBF) is widely used as pro-fluorescent probe substrate for CYP activity and inhibition assays, but its use has been considered to be limited to traditional end-point assays.
Introduction
The human cytochrome P450 (CYP) enzymes play an important role in the metabolism of drugs and numerous other xenobiotics. Inhibition of CYP enzymes is a common mechanism which can lead to drug interactions. These can evoke severe adverse effects, they have resulted in early termination of drug development, refusal to obtain approval, prescribing restrictions, and even withdrawal of drugs from the market (Wienkers and Heath, 2005; Kalgutkar et al., 2007; Pelkonen et al., 2008) .
CYP inhibition can be categorized as either reversible or irreversible. Irreversible inactivation is generally of greater concern than reversible inhibition as it can result in more profound and prolonged effects (Ghanbari et al., 2006; Kalgutkar et al., 2007) . There is increasing awareness that many clinically relevant drug interactions involving CYP inhibition are mediated by irreversible mechanism-based inactivation (MBI) (Ghanbari et al., 2006; Grime et al., 2009 ).
Today potential in vivo effects of drug interactions caused by competitive inhibitors can be fairly well predicted from in vitro CYP kinetics. The current challenge is to detect time-and concentration-dependent effects of irreversible and quasi-irreversible inactivators among large numbers of early phase compounds in the drug development pipeline (Wienkers and Heath, 2005; Fowler and Zhang, 2008) . This is especially important as failure to consider MBI in vitro can lead to serious underestimation of drug interaction magnitude in vivo, particularly when one is trying to predict drug interactions from in vitro data based upon competitive models (Bjornsson et al., 2003; Polasek and Miners, 2007) .
The updated regulatory guidances by the U.S. Food and Drug Administration (FDA, 2006) and European Medicines Agency (EMA, 2010) for in vitro drug interaction studies include recommendations that drug candidates need to be tested for time-dependent and mechanismbased inactivator properties. Recently, a team of scientists from 16 pharmaceutical research organizations recommended the use of a tiered approach wherein abbreviated assays are first used to determine whether or not new chemical entities demonstrate time-dependent inhibition, followed by more thorough inactivation studies for those that do (Grimm et al., 2009 ).
Current in vitro inactivation research methodologies have been criticized for being significantly influenced by the wide range in experimental conditions, complicating comparison across studies and jeopardizing clinical predictions. In addition, these complex experiments offer limited mechanistic insight (Ghanbari et al., 2006; Riley et al., 2007; Fowler and Zhang, 2008; Obach, 2009; Zhou and Zhou, 2009) . Recently, Fairman and co-workers (2007) proposed an alternative in vitro approach for the investigation of presteady state kinetics of CYP1A2 inactivation, referred to as progress curve analysis. Progress curve analysis uses an "all-in" approach where the enzyme is exposed simultaneously to probe substrate and inactivator while enzyme activity is monitored throughout the inactivation. This type of analysis has long been an accepted tool for measuring presteady state inhibition kinetics for a variety of physiological enzymes (Fairman et al., 2007; Obach, 2009; Zhou and Zhou, 2009 ).
Dibenzylfluorescein (DBF) is widely used as a pro-fluorescent probe substrate especially for CYP2C8, CYP2C9, CYP2C19, CYP3A4, and aromatase (CYP19) in high-throughput assays.
CYP2C19 was chosen as the target enzyme in this study as it metabolizes several widely used drugs, such as proton pump inhibitors (Pelkonen et al., 2008) . Recent data indicate that inhibition
6 of CYP2C19 may lead to reduction of clinical efficacy of the antithrombotic prodrug clopidogrel (Wallentin, 2009) . The DBF assay is based on the general principles originally published by Crespi and co-workers (1997; 2000) . The utility of DBF for kinetic assays with continuous data acquisition has been questioned since the initial metabolite of DBF (fluorescein benzyl ester) requires very alkaline conditions for further hydrolysis to maximize the fluorescence intensity (Crespi and Stresser, 2000; Miller et al., 2001 ).
The purpose of this study was to 1) characterize the properties of DBF as a probe substrate for CYP2C19 enzyme activity and inhibition assays, 2) assess whether DBF can be used as probe substrate in real-time kinetic assay, and 3) demonstrate the use of the progress curve analysis approach for rapid identification of time-dependent CYP inactivators as well as the analysis of key inactivation kinetic parameters. 103.59, 115.10, 128.11, 128.44, 128.48, 129.85, 130.09, 130.25, 130.30, 131.33, 132.72, 133.96, 134.01, 153.81, 157.16, 165.42 111.21, 111.28, 112.22, 112.30, 123.98, 125.03, 126.73, 127.47, 128.19, 128.67, 129.09, 129.33 ,
129. 71, 135.09, 136.23, 152.43, 152.48, 153.11, 157.73, 160.47, 169.93 Three kinds of blank samples were used: the first did not contain the CYP enzyme, the second lacked the NADPH-regenerating system, and the third lacked DBF. Otherwise the blanks were treated similarly to the enzyme-catalyzed samples. Each sample was assayed in duplicate. The samples were incubated for 45 min at 37°C. The reactions were terminated by rapid cooling to 4°C and after centrifugation, the supernatants were analyzed by LC-MS. Pure DBF, fluorescein benzyl ester, fluorescein benzyl ether, and fluorescein (all 10 µM) were used as standards and were analyzed in the absence and presence of 2 M NaOH. All samples were analyzed with a FinniganLTQ (Thermo, San Jose, CA) mass spectrometer using positive electrospray ionization and full scan or MS/MS measurements. The compounds were separated using a Agilent 1200HPLC system (Waldbronn, Germany) equipped with a 50 x 2 mm Gemini C18 column Prerequisites for kinetic assay. The initial prerequisites for a real-time kinetic assay were investigated using the end-point assay procedure by assessing if enzyme activity could be detected without the use of 2 M NaOH. This was carried out by comparing signal-to-noise-ratios between an enzyme-catalyzed sample and two blank (non-enzyme-catalyzed) samples. The experimental conditions were as described in Table 1 . The reactions were initiated by adding 50 µl of the NADPH-regenerating system after a 10-min preincubation at 37°C, and were subsequently incubated for 30 min at 37°C in dark. Blank I was similar to the control (enzymecatalyzed) sample except that 110 µl of 2 M NaOH was added into the wells before addition of the NADPH-regenerating system. Blank II lacked the enzyme. After measuring fluorescence at the end of the 30-min incubation, 110 µl of 2 M NaOH was added into the wells containing control and blank II samples, and the fluorescence was measured again.
Real-time kinetic assay. Real-time kinetic assays were conducted at 37°C in a Victor2 plate scanner using the experimental conditions in Table 1 . Blank samples were treated similarly to the enzyme-catalyzed samples but in the absence of CYP enzyme. Reactions were initiated by
1 1 addition of DBF (experiment A) or the NADPH-regenerating system (experiment B). Experiment C was conducted by measuring first the substrate in a Victor2 plate scanner for 15-min at 37°C, after which the prewarmed enzyme and the NADPH-regenerating system were added into the wells, and immediately after that the actual reaction incubation and fluorescence data acquisition was carried out at 1-minute intervals for 45 minutes. Each experiment was performed in duplicate. In addition, the linearity of the CYP2C19 catalyzed reaction with respect to enzyme concentration and incubation time was investigated by using varying amounts (0.125-2 pmol) of the enzyme. Progress curve analysis. The procedure involving the 15-min initial measurement of substrate as shown in Fig. 3C was used in progress curve analysis. In these experiments, the enzyme is exposed simultaneously to the substrate and inactivator, and enzyme activity is monitored
1 2 throughout the process (real-time kinetic assay). Progress curve experiments were carried out by evaluating two known mechanism-based (time-dependent) inactivators, isoniazid and ticlopidine, and one known reversible (time-independent) inhibitor, tranylcypromine. Seven different concentrations of each test compound were used: 2.74-4000 µM for isoniazid, 0.14-100 µM for ticlopidine, and 0.14-100 µM for tranylcypromine. These concentrations were selected to ensure a wide range of inactivation across the 45-min time course. Isoniazid and ticlopidine were dissolved in water, and tranylcypromine was dissolved in acetonitrile (ACN) and then further diluted with water. Consequently, the final solvent concentrations in the incubations did not exceed 2.2 %. Controls were treated similarly but without the presence of inactivators. The obtained fluorescence data were analyzed to determine the key kinetic parameters and mechanistic information of the inactivation process.
Each progress curve were fitted by Eq. 1 (Copeland, 2005) (Table 2 ). Fluorescein benzyl ester was formed in the CYP2C19-catalyzed reaction as a major metabolite, and minor amounts of fluorescein benzyl ether were also detected. Prerequisites for kinetic assay. The optimal conditions for the kinetic assay were examined by comparing fluorescence intensities between enzyme-catalyzed sample and two kinds of blank samples, and by evaluating the effects of NaOH on fluorescence intensity. The results are summarized in Table 3 . An acceptable signal-to-noise ratio was achieved during the 30-min incubation without addition of 2 M NaOH to the samples, as the fluorescence intensity was 12-fold higher in the enzyme-catalyzed samples than in Blank II (no enzyme) sample. In contrast, the fluorescence intensity was only about 2-3-fold higher in the enzyme-catalyzed samples than in Blank I (NaOH added before initiating the reaction). One important finding was that the signal-to-noise ratio was about 5 times greater between the enzyme sample and blank II than between enzyme sample and blank I. Addition of 2 M NaOH at the end of incubation resulted in only an 1.5-fold increase in fluorescence intensity. The result showed that it is feasible to detect enzyme activity without the use of 2 M NaOH, and blank II is a better choice for assessing background noise compared to blank I.
Real-time kinetic assay. The progress of the CYP-mediated catalytic reaction can be observed from the kinetic readouts as shown in Fig. 3 . The fluorescence intensity of DBF is declined to the steady state value during the 15-min initial measurement, allowing for detection of the linear reaction kinetics from the very beginning of the reaction (Fig. 3C) . (Fig. 6 ).
The K obs values were replotted against inactivator concentrations, and fitted to the Eq. 2 (Fig. 7) .
The determined K I and k inact values are presented in Table 4 . Tranylcypromine showed concentration-but not time-dependent inhibition determined by its linear progress curves at each concentration. Thus it was analyzed by linear fitting of each concentration as the relative reaction velocity can be determined from the slope of a linear fit, and IC 50 value was determined via standard methodologies (4.72 ± 0.30 µM), and then converted to an absolute inhibition constant 1 7
Discussion
In the present study we describe development of a simple, direct and informative fluorometric method for the assessment of CYP2C19 enzyme inactivation kinetics. The well known inactivators were used to test the method. Isoniazid and ticlopidine were chosen because clinically relevant interactions between them and substrates of CYP2C19 have been reported and they are known to act via MBI (Donahue et al., 1997; Tateishi et al., 1999; Nishimura et al., 2003; Richter et al., 2004; Kalgutkar et al., 2007; Venkatakrishnan and Obach, 2007) . The selected competitive inhibitor, tranylcypromine, is commonly used as positive control compound for CYPC19 inhibition studies (BD Gentest, 2000; Lin et al., 2007) .
The data show that 2 M NaOH is not required for the enzyme activity determinations using DBF as the probe substrate as the fluorescence intensity of the metabolite formed (fluorescein benzyl ester) is 120-fold higher than that of DBF. The transformation of fluorescein benzyl ester to fluorescein in the presence of 2 M NaOH is consistent with the reports of its use in the end-point assays (Miller et al., 2001; Hong et al., 2008) . However, it is not desirable that at the same time DBF is transformed to fluorescein benzyl ether in the presence of 2 M NaOH which also increases the background fluorescence intensity and causes significant deterioration in the sensitivity, i.e., signal-to-noise-ratio.
Therefore, CYP2C19 enzyme activity can be followed in real time using DBF as the substrate.
The product formation is linear from the very beginning of the reaction, and the IC 50 values calculated from the progress curves are comparable with the results obtained with the traditional end-point assay and correlated well with literature data (a range of 1.9-9 µM) (BD Gentest, 2000;
1 8 Dierks et al., 2001; Lin et al., 2007) . Kinetic assay provides the most reliable means of accurately determining reaction velocity from the slope of a plot of signal versus time, i.e., it is purely a result from the enzyme activity itself. Based on these experiments, the observed spontaneous quenching of DBF fluorescence is due to some fluorometric phenomenon instead of decomposition of the compound. The other related compounds possess higher fluorescence intensities than DBF.
The full progress curve of an enzymatic reaction contains an abundance of valuable kinetic information, and allows investigation of both reversible and irreversible components of the reaction mechanisms, and thus provides more information in one experiment. All irreversible enzyme inactivators display slow binding kinetics in progress curve analysis, and the slow onset of inhibition is best studied by following progress curves. Time-dependent inactivation converts the linear progress curve seen in the absence of the inactivator into a curvilinear function so that the degree of inhibition at a fixed concentration of compound will vary over time. Thus the enzyme reaction progress curve will be nonlinear, and reflect two distinct velocities for the reaction (Copeland, 2005) . This behavior was seen with the known time-dependent inactivators isoniazid and ticlopidine but not with the known time-independent inhibitor, tranylcypromine.
For time-dependent irreversible/quasi-irreversible inactivators, the value of k obs is generally expected to increase over a certain range of inactivator concentrations and then to undergo saturation at higher concentrations (Kalgutkar et al., 2007) . The first step involves reversible binding of the inactivator to the enzyme, often under rapid equilibrium conditions. For mechanism-based inactivators, the second step involves some bioactivation/chemistry of the covalent bond formation or transformation into metabolic intermediate (MI) products that
1 9 coordinate tightly to the heme iron atom of CYP enzyme. This behavior (saturation) was also seen with isoniazid and ticlopidine in this study pointing to a two-step inactivation mechanism.
All mechanism-based inactivators are competitive with the normal substrate of the enzyme, because they rely on the catalytic mechanism of the enzyme active site. The presence of substrate can hinder the access of the inactivator to the enzyme, i.e. the substrate has to be at a relatively low concentration (K m ) so that it does not completely block the enzyme inactivation process (Ghanbari et al., 2006) . For that reason, the probe substrate at the concentration corresponding to its measured apparent K m (data not shown) was used in the experiments and this was taken into account when determining kinetic constants of the inactivation. The determined inactivation kinetic constants (K I and k inact ) for isoniazid and ticlopidine correlated with published data (Wen et al., 2002; Nishimura et al., 2003; Polasek et al., 2006; Kalgutkar et al., 2007; Venkatakrishnan and Obach, 2007; Nishiya et al., 2009 ).
This progress curve analysis methodology allows also estimates of the initial binding equilibrium as reflected in the magnitude of reduction of v i by the inactivator against respective control, as described by Fairman and co-workers (Fairman et al., 2007) . In our study, v i was plotted against initial inactivator concentration but they showed no significant inhibition across the concentration range (<40-50 % inhibition at any concentration tested) so that no estimation of K i could be made.
In conclusion, time-dependent inhibition is one of the major distinguishing features between reversible and irreversible/quasi-irreversible inhibition. It thus provides a useful screening approach for identifying potential mechanism-based inactivators in early drug interaction studies for pharmaceuticals under development. This is especially important, because it has become widely appreciated that detection and amelioration of time-dependent inactivation is a crucial aspect in drug interaction optimization for novel compounds (Polasek and Miners, 2007; Fowler and Zhang, 2008) . DBF characterization, kinetic assay, and the progress curve analysis approach together offer a new response and improvement for the current challenge. The present work has shown that the widely used CYP substrate, DBF, is suitable for use in a progress curve analysis approach, i.e. this is a rapid and reliable method that can be used as an initial screen to help identify compounds that require more detailed investigations. However, this approach will require further evaluation with a broader set of CYP enzymes and inactivators before it is fully exploitable. indicate a two-step inactivation mechanism due to a saturable step before inactivation.
